API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-receives-fda-approval-to-proceed-with-phase-ii-clinical-trial-of-ropidoxuridine-for-treatment-of-patients-with-glioblastoma-302027844.html
https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-submits-ind-application-to-the-us-fda-for-ropidoxuridine-phase-ii-clinical-trial-for-patients-with-glioblastoma-302010823.html
https://www.prnewswire.com/news-releases/shuttle-pharma-announces-results-of-pre-ind-meeting-with-fda-for-ropidoxuridine-phase-ii-clinical-trial-for-patients-with-glioblastoma-301937085.html
https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-engages-ui-pharmaceuticals-for-formulation-and-clinical-batch-manufacture-of-ropidoxuridine-for-brain-tumor-clinical-trial-301767507.html